Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI InnovationPRNewsWire · Sep 9, 2026
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?Defense World · Aug 20, 2026
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyPRNewsWire · Aug 19, 2026
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer ModelsPRNewsWire · Aug 17, 2026
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200-Day Moving Average – Time to Sell?Defense World · Aug 4, 2026
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion MarketPRNewsWire · Jul 28, 2026Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 2, 2026 | -$3.12 | -$2.86 | Beat |
| Jul 8, 2026 | -$3.04 | -$2.32 | Beat |
| Mar 31, 2026 | -$0.51 | -$0.92 | Miss |
| Nov 26, 2025 | -$4.32 | -$0.33 | Beat |
| Aug 28, 2025 | -$0.83 | -$0.63 | Beat |
| May 22, 2025 | -$0.89 | -$0.62 | Beat |